Eisai Urges Dismissal of Suit Linking Belviq Diet Drug to Cancer

Sept. 2, 2020, 6:43 PM

Eisai Inc. urged a federal court in Louisiana to toss a woman’s suit linking her breast cancer to its withdrawn weight loss drug Belviq, saying her claims are either not recognized by Louisiana product liability law or not adequately pleaded.

Stephanie Fuller said she used the prescription weight-loss drug for approximately three months, ending in October, and her cancer was diagnosed about eight months later.

Fuller sued distributor Eisai and manufacturer Arena Pharmaceuticals Inc.

Her negligence, strict liability, breach of implied warranty, and fraud-based claims fall outside the Louisiana Product Liability Act, the state’s exclusive remedy for product liability claims, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.